Key Specifications Table
|Empirical Formula||CAS #|
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|400036-25MG||Glass bottle||25 mg||
|Overview||A bis-hydroxybenzoate compound that acts as a fast-acting, irreversible blocker of glucose transport by GLUT1 in red blood cells. Shown to rapidly inhibit glucose transport in cancer cells (IC50 ~ 500 nM in A549 cells) and block proliferation. Its inhibitory effects are more pronounced in hypoxic cancer cells. It binds directly to GLUT1 involving three hydrogen bonds, one each with Asn34, Arg126, and Trp412. Also shown to reduce the levels of GLUT1 protein, intracellular ATP levels, and glycolytic enzymes and increase the level of AMPK in tumor cells. Preferentially induces cell cycle arrest and causes senescence and necrosis in red blood cells and tumor cells (IC50 = 10 µM) over non cancerous cells and synergizes the anti-tumor effects of cisplatin (Cat. No. 232120) and paclitaxel (Cat. No. 580555). Also, effectively suppresses tumor growth in human A549 lung cancer grafted nude mice model (10 mg/kg, i.p., daily).|
|Synonyms||GLUT Inhibitor IV, WZB117, 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate)|
|References||Liu. Y., et al. 2012. Mol. Cancer Ther. 11, 1672.|
|Structure formula Image|
|Application||Glucose Transporter Inhibitor IV, WZB117, CAS 1223397-11-2, is a fast-acting, irreversible blocker of GLUT1 in RBCs. Also inhibits glucose transport in cancer cells (IC50 ~ 500 nM in A549 cells).|
|Purity||≥98% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Liu. Y., et al. 2012. Mol. Cancer Ther. 11, 1672.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.